[{"id":"219d1e0e-b56c-4bab-85c7-f221ec0d5b47","acronym":"","url":"https://clinicaltrials.gov/study/NCT05252390","created_at":"2022-02-23T19:55:04.757Z","updated_at":"2024-07-02T16:35:00.496Z","phase":"Phase 1/2","brief_title":"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05252390","lead_sponsor":"Nuvation Bio Inc.","biomarkers":" BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Xtandi (enzalutamide) • NUV-868"],"overall_status":"Recruiting","enrollment":" Enrollment 657","initiation":"Initiation: 03/29/2022","start_date":" 03/29/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-05-29"},{"id":"01bffa3c-9006-4894-8107-d61b57731dac","acronym":"","url":"https://clinicaltrials.gov/study/NCT02717962","created_at":"2021-07-05T16:52:37.869Z","updated_at":"2024-07-02T16:35:28.400Z","phase":"Phase 2","brief_title":"Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting","source_id_and_acronym":"NCT02717962","lead_sponsor":"Kintara Therapeutics, Inc.","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide • dianhydrogalactitol (VAL-083)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 01/20/2017","start_date":" 01/20/2017","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 03/30/2024","study_completion_date":" 03/30/2024","last_update_posted":"2023-11-22"},{"id":"db290688-b9fc-48ab-8e7b-dd66203a479d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03050736","created_at":"2021-01-18T15:01:27.039Z","updated_at":"2024-07-02T16:35:28.518Z","phase":"Phase 2","brief_title":"Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression","source_id_and_acronym":"NCT03050736","lead_sponsor":"Kintara Therapeutics, Inc.","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dianhydrogalactitol (VAL-083)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/17/2017","start_date":" 12/17/2017","primary_txt":" Primary completion: 11/22/2021","primary_completion_date":" 11/22/2021","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2023-11-21"},{"id":"0e10acf9-5a67-407c-ab46-05c9fe46a0db","acronym":"","url":"https://clinicaltrials.gov/study/NCT00710710","created_at":"2021-07-05T16:04:35.612Z","updated_at":"2024-07-02T16:36:11.025Z","phase":"Phase 2","brief_title":"Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer","source_id_and_acronym":"NCT00710710","lead_sponsor":"Boehringer Ingelheim","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BI2536"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 10/14/2008","primary_completion_date":" 10/14/2008","study_txt":" Completion: 10/14/2008","study_completion_date":" 10/14/2008","last_update_posted":"2022-05-04"},{"id":"8f7947e2-9124-4105-8e09-87320d4b0bca","acronym":"","url":"https://clinicaltrials.gov/study/NCT03205176","created_at":"2021-01-18T15:48:59.636Z","updated_at":"2024-07-02T16:36:30.672Z","phase":"Phase 1","brief_title":"AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas","source_id_and_acronym":"NCT03205176","lead_sponsor":"AstraZeneca","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • SRA515"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 06/30/2017","start_date":" 06/30/2017","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 04/08/2021","study_completion_date":" 04/08/2021","last_update_posted":"2021-05-06"},{"id":"5a84f8a3-f42b-4227-a0cd-33a7cd9fe530","acronym":"","url":"https://clinicaltrials.gov/study/NCT01713582","created_at":"2021-07-05T16:23:11.611Z","updated_at":"2024-07-02T16:36:35.612Z","phase":"Phase 1","brief_title":"A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)","source_id_and_acronym":"NCT01713582","lead_sponsor":"Oncoethix GmbH","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e birabresib (OTX015)"],"overall_status":"Completed","enrollment":" Enrollment 141","initiation":"Initiation: 12/14/2012","start_date":" 12/14/2012","primary_txt":" Primary completion: 01/20/2017","primary_completion_date":" 01/20/2017","study_txt":" Completion: 01/20/2017","study_completion_date":" 01/20/2017","last_update_posted":"2021-01-26"},{"id":"a79a3ada-bd2e-4436-944e-2fbb8127fac0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02259114","created_at":"2021-01-18T10:36:46.682Z","updated_at":"2024-07-02T16:36:35.600Z","phase":"Phase 1","brief_title":"A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)","source_id_and_acronym":"NCT02259114","lead_sponsor":"Oncoethix GmbH","biomarkers":" KRAS • ALK • NUTM1","pipe":" | ","alterations":" KRAS mutation • ALK rearrangement • ALK fusion","tags":["KRAS • ALK • NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ALK rearrangement • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e birabresib (OTX015)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 10/23/2014","start_date":" 10/23/2014","primary_txt":" Primary completion: 03/03/2017","primary_completion_date":" 03/03/2017","study_txt":" Completion: 03/03/2017","study_completion_date":" 03/03/2017","last_update_posted":"2021-01-26"},{"id":"e2d15399-6c48-4d6d-b73e-419170efa3e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01478178","created_at":"2021-01-18T06:10:05.513Z","updated_at":"2024-07-02T16:37:26.384Z","phase":"Phase 1/2","brief_title":"Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma","source_id_and_acronym":"NCT01478178","lead_sponsor":"DelMar Pharmaceuticals, Inc.","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dianhydrogalactitol (VAL-083)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 10/01/2016","study_completion_date":" 10/01/2016","last_update_posted":"2017-01-20"}]